D. E. Shaw & Co., Inc. Erasca, Inc. Transaction History

D. E. Shaw & Co., Inc.

$100 Billion
Q1 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Erasca, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 31,429 shares of ERAS stock, worth $43,057. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,429

Previous 369,254 91.49%

Holding current value

$43,057

Previous $926,000 95.36%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.28 - $2.75 $432,416 - $929,018	-337,825 Reduced 91.49%	31,429 $43,000
Q4 2024 Feb 14, 2025	SELL	$2.44 - $3.23 $279,555 - $370,067	-114,572 Reduced 23.68%	369,254 $926,000
Q3 2024 Nov 14, 2024	BUY	$2.17 - $3.28 $365,152 - $551,935	168,273 Added 53.33%	483,826 $1.32 Million
Q2 2024 Aug 14, 2024	SELL	$1.79 - $2.63 $9,256 - $13,599	-5,171 Reduced 1.61%	315,553 $744,000
Q1 2024 May 15, 2024	BUY	$1.67 - $2.55 $364,863 - $557,126	218,481 Added 213.69%	320,724 $660,000
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.49 $170,745 - $254,585	102,243 New	102,243 $217,000
Q1 2023 May 15, 2023	SELL	$2.74 - $4.44 $205,784 - $333,461	-75,104 Reduced 66.47%	37,880 $114,000
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $374,015 - $823,988	96,148 Added 571.09%	112,984 $486,000
Q3 2022 Nov 14, 2022	SELL	$5.82 - $10.68 $547,708 - $1.01 Million	-94,108 Reduced 84.82%	16,836 $131,000
Q2 2022 Aug 15, 2022	SELL	$4.58 - $8.72 $316,638 - $602,857	-69,135 Reduced 38.39%	110,944 $618,000
Q1 2022 May 16, 2022	BUY	$8.6 - $15.48 $1.55 Million - $2.79 Million	180,079 New	180,079 $1.55 Million

Others Institutions Holding ERAS

# of Institutions

162

Shares Held

222M

Call Options Held

20.6K

Put Options Held

5.7K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $167M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account